Lexicon Pharmaceuticals, Inc.
LXRXNASDAQHealthcare● Active
$1.88
$-0.03(-1.57%)
Market Cap$835088480
P/E Ratio—
52W High$2.53
52W Low$0.64
Lexicon Pharmaceuticals, Inc. (LXRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LXRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($50.34M) | ($200.40M) | ($177.12M) | ($101.94M) | ($87.76M) |
| Depreciation & Amort. | $0.62M | $0.53M | $0.55M | $0.43M | $0.29M |
| Stock-Based Comp. | $12.52M | $13.50M | $14.34M | $11.52M | $10.58M |
| Change in Working Capital | ($26.89M) | $14.24M | $2.66M | $0.40M | ($10.23M) |
| Net Cash from Operations | ($67.85M) | ($178.78M) | ($161.90M) | ($88.85M) | ($87.02M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | ($1.03M) | ($0.47M) | ($1.33M) | ($1.22M) |
| Purchases of Investments | ($143.55M) | ($338.05M) | ($223.34M) | ($133.95M) | ($34.26M) |
| Sales of Investments | $252.86M | $314.40M | $173.87M | $64.20M | $37.59M |
| Net Cash from Investing | $113.02M | ($15.38M) | ($49.94M) | ($71.08M) | $2.11M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($1.73M) | ($0.82M) | ($0.86M) | ($2.67M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($48.00M) | $0.00M | $49.96M | $48.87M | ($11.70M) |
| Net Cash from Financing | ($48.50M) | $238.35M | $187.96M | $142.21M | $22.71M |
| Free Cash Flow | |||||
| Free Cash Flow | ($67.85M) | ($179.81M) | ($162.37M) | ($90.18M) | ($88.24M) |
| FCF Margin %(computed) | -136.24% | -578.52% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Lexicon Pharmaceuticals, Inc. data
About Lexicon Pharmaceuticals, Inc. (LXRX) Cash Flow Statement
Lexicon Pharmaceuticals, Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.07B) for 2025 — a FCF margin of -136.24%. Capital expenditure was $0.00B.
Frequently asked questions
LXRX · 4 questionsLexicon Pharmaceuticals, Inc. generated free cash flow of ($0.07B) for 2025, up 62.3% year-over-year.
LXRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10